tbuckley/cabot-search huggingface dataset:
Early Response Predicts Long-Term Improvement or Stabilization of Persons with Multiple Sclerosis Treated with Hematopoietic Stem Cell Transplantation
Authors: Iván Murrieta-Álvarez, Montserrat Rivera-Álvarez, Gilberto David Elias-de-la-Cruz, Luisa Fernanda Sánchez-Valledor, Carmina Alejandra Córdova-Ramírez, Yahveth Cantero-Fortiz, Andrés A. León-Peña, Martin Ojeda-Laguna, José Manuel Priesca-Marin, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Arguelles
Journal: Blood (2020)
Comparative Efficacy of CC-486 Versus Injectable Azacitidine (AZA) in Patients (Pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy: Findings from an Indirect Treatment Comparison (ITC)
Authors: Clara Chen, Tim Disher, Muhaimen Siddiqui, Ignazia La Torre, Barry Skikne, Beatrice Suero, Heather Cameron, Roya Gavanji, Chris Cameron
Journal: Blood (2020)
Progress Toward Global Eradication of Dracunculiasis, January 2019–June 2020
Authors: Donald R. Hopkins, Adam J. Weiss, Sharon L. Roy, Sarah Yerian, Sarah G.H. Sapp
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Dracunculiasis (Guinea worm disease) is caused by the parasite Dracunculus medinensis and is acquired by drinking water containing copepods (water fleas) infected with D. medinensis larvae. The worm typically emerges through the skin on a lower limb approximately 1 year after infection, resulting in pain and disability (1). There is no vaccine or medicine to treat the disease; eradication efforts rely on case containment* to prevent water contamination. Other interventions to prevent infection include health education, water filtration, chemical treatment of unsafe water with temephos (an organophosphate larvicide to kill copepods), and provision of safe drinking water (1,2). The worldwide eradication campaign began in 1980 at CDC (1). In 1986, with an estimated 3.5 million cases† occurring each year in 20 African and Asian countries§ (3), the World Health Assembly (WHA) called for dracunculiasis elimination (4). The global Guinea Worm Eradication Program (GWEP), led by the Carter Center and supported by the World Health Organization (WHO), United Nations Children's Fund, CDC, and other partners, began assisting ministries of health in countries with dracunculiasis. This report, based on updated health ministry data (4), describes progress made during January 2019-June 2020 and updates previous reports (2,4,5). With only 54 human cases reported in 2019, 19 human cases reported during January 2019-June 2020, and only six countries currently affected by dracunculiasis (Angola, Chad, Ethiopia, Mali, South Sudan, and importations into Cameroon), the achievement of eradication is within reach, but it is challenged by civil unrest, insecurity, and lingering epidemiologic and zoologic concerns, including 2,000 reported animal cases in 2019 and 1,063 animal cases in 2020, mostly in dogs. All national GWEPs remain fully operational, with precautions taken to ensure safety of program staff members and community members in response to the coronavirus disease 2019 (COVID-19) pandemic.
A Novel Multimodal Next Generation Sequencing Assay with Total Nucleic Acid Input to Provide Comprehensive Genomic Profiling for Hematologic Malignancies
Authors: Yongxin Yu, Francys Alarcon, Yanglong Mou, Segun C Jung, Hyunjun Nam, Brad Thomas, Lauryn Keeler, Eve Shinbrot, Christophe Magnan, Tessa Weiss, Ryan Bender, Shi-Ping Jiang, Sally Agersborg, Lawrence Weiss, Fei Ye, Vincent Funari
Journal: Blood (2020)
Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia
Authors: Jennifer A. Woyach, James S. Blachly, Kerry A. Rogers, Seema A Bhat, Michael R. Grever, Adam S. Kittai, Mojgan Jianfar, Gerard Lozanski, David M. Weiss, Barbara L. Andersen, Priti Patel, Veerendra Munugalavadla, Anna Butturini, Yan Xu, Min Hui Wang, John C. Byrd
Journal: Blood (2020)
Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)
Authors: Jinming Song, Hailing Zhang, Xiaohui Zhang, Mohammad Hussaini, Ning Dong, Lynn C Moscinski, Kenneth H. Shain, Melissa Alsina, Taiga Nishihori, Ling Zhang
Journal: Blood (2020)
Silencing of miR-138-5p sensitizes bone anabolic action to mechanical stimuli
Authors: Zhihao Chen, Fan Zhao, Chao Liang, Lifang Hu, Dijie Li, Yan Zhang, Chong Yin, Lei Chen, Luyao Wang, Xiao Lin, Peihong Su, Jianhua Ma, Chaofei Yang, Ye Tian, Wenjuan Zhang, Yu Li, Songlin Peng, Weiyi Chen, Ge Zhang, Airong Qian
Journal: Theranostics (2020)

Emerging evidence is revealing that microRNAs (miRNAs) play essential roles in mechanosensing for regulating osteogenesis. However, no mechanoresponsive miRNAs have been identified in human bone specimens. Methods: Bedridden and aged patients, hindlimb unloaded and aged mice, and Random Positioning Machine and primary aged osteoblasts were adopted to simulate mechanical unloading conditions at the human, animal and cellular levels, respectively. Treadmill exercise and Flexcell cyclic mechanical stretching were used to simulate mechanical loading in vivo and in vitro, respectively. Results: Here, we found increased miR-138-5p levels with a lower degree of bone formation in bone specimens from bedridden and aged patients. Loss- and gain-of-function studies showed that miR-138-5p directly targeted microtubule actin crosslinking factor 1 (MACF1) to inhibit osteoblast differentiation under different mechanical conditions. Regarding translational medicine, bone-targeted inhibition of miR-138-5p attenuated the decrease in the mechanical bone anabolic response in hindlimb unloaded mice. Moreover, bone-targeted inhibition of miR-138-5p sensitized the bone anabolic response to mechanical loading in both miR-138-5p transgenic mice and aged mice to promote bone formation. Conclusion: These data suggest that miR-138-5p as a mechanoresponsive miRNA accounts for the mechanosensitivity of the bone anabolic response and that inhibition of miR-138-5p in osteoblasts may be a novel bone anabolic sensitization strategy for ameliorating disuse or senile osteoporosis.
A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Authors: Jie Wang, Adam S. Asch, Nada Hamad, Andrew Weickhardt, Monika Tomaszewska-Kiecana, Monika Dlugosz-Danecka, Halyna Pylypenko, Shakeela Bahadur, Susanna Ulahannan, Janine Koucheki, Jichao Sun, Hua Li, Francine Chen, Xiaoyu Zhang, John Muth, Patrick Kaminker, Paul Moore, Bradley James Sumrow
Journal: Blood (2020)
Oxygen Gradient Ektacytometry-Derived Biomarkers Are Associated with the Occurrence of Cerebral Infarction, Acute Chest Syndrome and Vaso-Occlusive Crisis in Sickle Cell Disease
Authors: Minke A.E. Rab, Celeste K. Kanne, Brigitte A. van Oirschot, Jennifer Bos, Camille Boisson, Maite E. Houwing, Celine Renoux, Marije Bartels, Erfan Nur, Marjon H. Cnossen, Philippe Joly, Romain Fort, Philippe Connes, Richard van Wijk, Vivien A. Sheehan, Eduard van Beers
Journal: Blood (2020)
AB1278 A CASE REPORT OF TOCILIZUMAB INDUCE RAPID REMISSION OF ADULT-ONSET STILL’S DISEASE WITH LIFE-THREATENING INTERSTITIAL LUNG DISEASE AND MACROPHAGE ACTIVATION SYNDROME
Authors: G. Zhang, W. Liu, T. Xu, X. Zhang
Journal: Annals of the Rheumatic Diseases (2020)

Background: Adult-onset still’s disease (AOSD) is a systemic inflammatory condition characterized by fevers, polyarthritis, skin rashes and increased leukocyte and neutrophil counts [1]. Sometimes life-threatening complications such as macrophage activation syndrome (MAS), disseminated intravascular coagulopathy (DIC) can be occurred without response to glucocorticoid and disease-modifying antirheumatic drugs (DMARDs). Objectives: To describe an AOSD patient with life-threatening interstitial lung disease (ILD) and MAS response to tocilizumab. Methods: This is a case report at our medical practice. Results: A 43-year-old man was hospitalized for a 2-week history of fever accompanying skin rashes, polyarthritis, sore throat, leukocytosis (the maximum leukocyte count 37.25×10 9 /L with 89.9% neutrophils), elevated levels of C-reactive protein (190.9mg/L) and ferritin level was very high (&gt;15000ng/ml), Several antibiotics were consequently used, but fever was on going. Chest CT displayed diffuse interstitial lung disease. Infectious diseases and lymphoma were excluded and AOSD with ILD was diagnosed. However, MAS occurred the 20 days later after the pulse of intravenous MP (MP 500mg×3days) following MP 40 mg/day, which cannot stop the situation deteriorating. The minimum total white blood cells, hemoglobin and platelets went down to 0.25×10 9 /l, 53g/l and 18×10 9 /l. Finally, tocilizumab rescued this patient from desperation. Conclusion: Tocilizumab was effective in AOSD with life-threatening ILD and MAS. References: [1]E. Feist, S. Mitrovic, and B. Fautrel, Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol 14 (2018) 603-618. Disclosure of Interests: None declared
FRI0474 IMMUNE CHECKPOINT INHIBITOR-INDUCED MUSCULOSKELETAL MANIFESTATIONS. A SYSTEMATIC REVIEW
Authors: F. Angelopoulou, I. Antonopoulos, D. Bogdanos, T. Dimitroulas, L. Sakkas, D. Daoussis
Journal: Annals of the Rheumatic Diseases (2020)

Background: Immune checkpoint inhibitors (ICI) are potent anti-cancer drugs that associate with a wide range of immune related adverse events (Ir-AE), including musculoskeletal manifestations. Objectives: We performed a systematic literature review of ICI-induced musculoskeletal manifestations aiming at exploring the following: 1) the prevalence of these manifestations and the time from first ICI administration to symptom onset, 2) the main clinical phenotypes and the type of treatment required to control symptoms (steroids/DMARDs), 3) the type of ICI (CTLA-4 vs PD-1/PD-L1 inhibitors) mostly associated with Ir-AE, 4) the percentage of patients with positive auto-antibodies and family history of autoimmune disease, 5) the percentage of patients requiring permanent ICI discontinuation due to musculoskeletal Ir-AE, 6) the association between musculoskeletal Ir-AE and oncologic response and 7) the risk of flare in patients with pre-existing autoimmune disease (PAD). Methods: An electronic (PubMed) search was performed aiming at identifying all studies reporting musculoskeletal Ir-AE. Results: We identified 3 prospective studies, 17 retrospective studies and 4 case series reporting 363 patients in total. Combined data from all 3 prospective studies provide a prevalence rate of 6.13%. Most patients were males (59.68%) and the vast majority (73%) were on programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors. Most studies report a median time of ≤ 12 weeks from first ICI administration to symptom onset. The main clinical phenotypes reported were: a) inflammatory arthritis (57.57%), b) myositis (14.04%) and c) polymyalgia rheumatica (PMR) (12.12%). A total of 256 patients required steroids (70.52%) and 67 patients (18.45%) were treated with DMARDs. From the 363 patients reported in total, 265 (73%) were treated with PD-1/PD-L1 inhibitors in sharp contrast to only 11 (3.03%) with CTLA4 inhibitors with the rest patients receiving combination immunotherapy Positive auto-antibodies and family history of any autoimmune disease were present in 18.48% and 19.04% of cases, respectively. Only a few patients (19%) had to discontinue treatment due to musculoskeletal Ir-AE. Two prospective studies show that significantly more patients with musculoskeletal Ir-AE exhibit a favorable oncologic response compared to patients not exhibiting such manifestations whereas retrospective studies show that 77.22% of patients with musculoskeletal Ir-AE have a good tumor response. Conclusion: One out of 15 patients treated with ICI will develop musculoskeletal Ir-AE; in most cases the severity of these manifestations is mild/moderate and usually ICI is continued. Rheumatologists should familiarize themselves with this new clinical entity and develop relevant therapeutic algorithms. Disclosure of Interests: None declared
CD22 Gating for Flow Cytometric Analysis in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia after CD19 CAR-T Therapy
Authors: Xinjian Yu, Pan Li, Heyuan Feng, Jian Kang, Xichang Zheng, Yunmei Zhang, Wenhong Yang, Tong Wu, Shuangyou Liu
Journal: Blood (2020)
Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial
Authors: Jessica Liegel, Richard M. Stone, Robert J. Soiffer, Dina Stroopinsky, Lina Bisharat, Maryam Rahimian, Emma Logan, Pavania Elavalakanar, Vincent T. Ho, Rizwan Romee, Donna S. Neuberg, Yiwen Liu, Lourdes M. Mendez, Ajoy L. Dias, Poorva Bindal, Anita Koshy, Shira Orr, Daniela Torres, Giulia Cheloni, Benjamin L. Ebert, Donald Kufe, David E. Avigan, Jacalyn Rosenblatt
Journal: Blood (2020)
Pre-Transplantation ST2 Levels and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation
Authors: Lars Klingen Gjærde, Sisse Rye Ostrowski, Niels Smedegaard Andersen, Lone Smidstrup Friis, Brian Kornblit, Søren Lykke Petersen, Ida Schjødt, Henrik Sengeløv
Journal: Blood (2020)
CAR-T Cells with High CAR Expression Intensity Have Improved I<i>n Vitro</i> and I<i>n Vivo</i> Anti-Lymphoma Effect without Functional Exhaustion
Authors: ANA Carolina Carolina CABALLERO González, Laura Escribà-García, Paula Pujol-Fernández, Eva Escudero-López, Rosanna Montserrat, Cristina Ujaldón-Miró, Jorge Sierra, Carmen Alvarez-Fernández, Javier Briones
Journal: Blood (2020)
The Burkitt Lymphoma International Prognostic Index (BL-IPI)
Authors: Adam J Olszewski, Lasse H. Jakobsen, Graham P. Collins, Kate Cwynarski, Veronika Bachanova, Kristie A. Blum, Kirsten M Boughan, Mark Bower, Alessia Dalla Pria, Alexey Danilov, Kevin A. David, Catherine Diefenbach, Fredrik Ellin, Narendranath Epperla, Umar Farooq, Tatyana A. Feldman, Alina S. Gerrie, Deepa Jagadeesh, Manali Kamdar, Reem Karmali, Shireen Kassam, Vaishalee P. Kenkre, Nadia Khan, Andreas Klein, Izidore S. Lossos, Matthew A. Lunning, Peter Martin, Nicolas Martinex-Calle, Silvia Montoto, Seema Naik, Neil Palmisiano, David Peace, Elizabeth H Phillips, Tycel J. Phillips, Craig A. Portell, Nishitha Reddy, Anna Santarsieri, Maryam Sarraf Yazdy, Knut B. Smeland, Scott E. Smith, Stephen D. Smith, Suchitra Sundaram, Parameswaran Venugopal, Adam Zayac, Xiao-Yin Zhang, Catherine Zhu, Chan Yoon Cheah, Tarec Christoffer El-Galaly, Andrew M. Evens
Journal: Blood (2020)
Etoposide, Cytarabine and Mitoxantrone- or Fludarabine, Cytarabine and Granulocyte Colony-Stimulating Factor-Based Intensive Reinduction Chemotherapy Is Recommended for Children with Relapsed Acute Myeloid Leukemia: The Results from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R Study
Authors: Hiroshi Moritake, Shiro Tanaka, Takako Miyamura, Hideki Nakayama, Norio Shiba, Akira Shimada, Kiminori Terui, Yuki Yuza, Katsuyoshi Koh, Hiroaki Goto, Harumi Kakuda, Akiko M Saito, Daisuke Hasegawa, Shotaro Iwamoto, Takashi Taga, Souichi Adachi, Daisuke Tomizawa
Journal: Blood (2020)
Abstract 413: Inhibition of Phospholipase A2 Preserves Endothelial Cell Migration in Presence of Lipid Oxidation Products
Authors: Priya Putta, Andrew H Smith, Pinaki Chaudhuri, Linda M Graham
Journal: Circulation Research (2020)

During vascular intervention oxidized low-density lipoprotein (oxLDL) and lysophosphatidylcholine (lysoPC) accumulate at the site of arterial injury, which inhibits endothelial cell (EC) migration, and impedes endothelium healing. We have previously shown that lysoPC activates canonical transient receptor potential 6 (TRPC6) channel that leads to a prolonged [Ca2+]i influx, causing the inhibition in EC migration. We hypothesize that lysoPC activates phospholipase A 2 (PLA 2 ) crucial for TRPC6 activation; PLA 2 acts on cellular membranes to release arachidonic acid that opens arachidonate regulated calcium channel to release the initial calcium required to trigger TRPC6, blocking PLA 2 will prevent the opening of TRPC6 channels, preserve migration and promote endothelium healing. After incubation of bovine aortic EC with ATK or Ax048 to block PLA2G4, or with BEL, FKGK11, or FKGK18 to block PLA2G6, the effect of lysoPC-induced TRPC6 externalization and EC migration was assessed. Reversible PLA2G6 pharmacological inhibitors maximally blocked lysoPC-induced TRPC6 externalization, arachidonic acid release and preserved EC migration; exemplified with biotinylation assay, arachidonate enzyme assay, and razor scrape migration assay respectively. Immunofluorescence microscopy for TRPC6 plasma membrane translocation and PLA 2 enzyme activity assay supported these findings. To further verify the specific isoforms involved in blocking TRPC6 externalization, siRNA mediated transient knockdown studies were performed with PLA2G4A, PLA2G4C, PLA2G6A, and PLA2G6B siRNAs in EA.hy926— human endothelial cell line. PLA2G6A and not PLAG6B/4A/4C downregulation completely blocked TRPC6 externalization and preserved migration comparable to control levels. These studies confirmed the role of PLA2G6A (a calcium-independent cytosolic phospholipase A 2 group VI β isoform) in blocking lysoPC-induced TRPC6 activation and preservation of EC migration. Additional studies are in progress to confirm in vivo relevance of these findings. Our results show the potential for developing PLA 2 targeted therapies to block TRPC6 activation and promote endothelium healing, thus improving the outcomes for patients undergoing cardiovascular intervention.
Preclinical Development of Edit-201, a Multigene Edited Healthy Donor NK Cell with Enhanced Anti-Tumor Function and Superior Serial Killing Activity in an Immunosuppressive Environment
Authors: Christopher M Borges, Kevin Wasko, Jared M Nasser, Kelly Donahue, Amanda Pfautz, Lincy P Antony, Glenn Leary, Steven Sexton, Richard A. Morgan, Karrie K Wong
Journal: Blood (2020)
Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease
Authors: Syeda Rahman, Andrew Srisuwananukorn, Robert E. Molokie, Michel Gowhari, Franklin Njoku, Faiz Ahmed Hussain, Edith A. Nutescu, Victor R. Gordeuk, Santosh L. Saraf, Jin Han
Journal: Blood (2020)
The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study
Authors: Garth Funston, Willie Hamilton, Gary Abel, Emma J. Crosbie, Brian Rous, Fiona M. Walter
Journal: PLoS Medicine (2020)

Background The serum biomarker cancer antigen 125 (CA125) is widely used as an investigation for possible ovarian cancer in symptomatic women presenting to primary care. However, its diagnostic performance in this setting is unknown. We evaluated the performance of CA125 in primary care for the detection of ovarian and non-ovarian cancers. Methods and findings We studied women in the United Kingdom Clinical Practice Research Datalink with a CA125 test performed between 1 May 2011–31 December 2014. Ovarian and non-ovarian cancers diagnosed in the year following CA125 testing were identified from the cancer registry. Women were categorized by age: <50 years and ≥50 years. Conventional measures of test diagnostic accuracy, including sensitivity, specificity, and positive predictive value, were calculated for the standard CA125 cut-off (≥35 U/ml). The probability of a woman having cancer at each CA125 level between 1–1,000 U/ml was estimated using logistic regression. Cancer probability was also estimated on the basis of CA125 level and age in years using logistic regression. We identified CA125 levels equating to a 3% estimated cancer probability: the "risk threshold" at which the UK National Institute for Health and Care Excellence advocates urgent specialist cancer investigation. A total of 50,780 women underwent CA125 testing; 456 (0.9%) were diagnosed with ovarian cancer and 1,321 (2.6%) with non-ovarian cancer. Of women with a CA125 level ≥35 U/ml, 3.4% aged <50 years and 15.2% aged ≥50 years had ovarian cancer. Of women with a CA125 level ≥35 U/ml who were aged ≥50 years and who did not have ovarian cancer, 20.4% were diagnosed with a non-ovarian cancer. A CA125 value of 53 U/ml equated to a 3% probability of ovarian cancer overall. This varied by age, with a value of 104 U/ml in 40-year-old women and 32 U/ml in 70-year-old women equating to a 3% probability. The main limitations of our study were that we were unable to determine why CA125 tests were performed and that our findings are based solely on UK primary care data, so caution is need in extrapolating them to other healthcare settings. Conclusions CA125 is a useful test for ovarian cancer detection in primary care, particularly in women ≥50 years old. Clinicians should also consider non-ovarian cancers in women with high CA125 levels, especially if ovarian cancer has been excluded, in order to prevent diagnostic delay. Our results enable clinicians and patients to determine the estimated probability of ovarian cancer and all cancers at any CA125 level and age, which can be used to guide individual decisions on the need for further investigation or referral.
Developing survivorship services in Ghana and Tanzania.
Authors: Nazima Jaffer Dharsee, Beatrice W Addai, Lisa Murray, Amanda Shewbridge, Maria Aresu, Susannah Jane Stanway, Sheila Small, Geraldine o'Gara, Seth A Wiafe, Theresa Wiseman
Journal: Journal of Clinical Oncology (2020)

e24132 Background: The incidence of breast cancer is increasing in low- &amp; middle- income countries (LMICs). Alongside attempts to reduce the disparity in cancer survival between high-income countries (HIC) &amp; LMICs, it is important that survivorship is well understood and managed in an evidence based, resource and culturally sensitive manner. This project aimed to develop knowledge, skills and services concerning living with and beyond breast cancer primary treatment. Methods: This 3-phase study used mixed methods. Phase 1 used participant observation and focus group interviews (FGIs) to scope experience, resources, current practice, and challenges to implementing a recovery package. In Phase 2 nurses used the adapted Holistic Needs Assessment (HNA) with 500 women in Tanzania and Ghana, who were also offered a recovery care plan and treatment summary following their breast cancer primary treatment. Data was entered into a macro database &amp; analysed using descriptive statistics. Phase 3 was the development of a culturally sensitive “Foundations in Cancer Care” training toolkit for nurses. The toolkit was based on a “train the trainer” model and included slides, an existing palliative care toolkit and exercises. The training programme consisted of 5 days teaching covering theory and practice. Data collection included: Initial FGIs to ascertain learning needs, confidence in knowledge &amp; skills, assessed pre &amp; post teaching course, and course evaluation. Data were analysed using descriptive statistics. Results: In Phase 1 six themes were identified concerning experience of breast cancer which included cultural beliefs &amp; practices and access to treatment &amp; support. Phase 2 data from Tanzania showed a similar level of unmet need at the end of treatment to a previous similar published analysis from the UK. Data from Ghana showed a much higher level of unmet need. Evaluation following Phase 3 showed a positive change in nurses’ confidence in their knowledge. Conclusions: This mixed methods three-phase study has documented experience, resources and current practise around breast cancer survivorship in two African centers treating breast cancer. The feasibility of using HNA to identify unmet needs in these women has been demonstrated and needs the identified. Results from the HNA informed a training toolkit which was implemented and positively received and could be adapted for use in other LMICs.